Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M BERK

Showing results (181-190 of 196) with videos related to

Pageof 20
Sort By:
Journal of Internal Medicine|February 3, 2021
Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivorsR Méndez, V Balanzá-Martínez, S C Luperdi, et al.
Acta Neuropsychiatrica|July 1, 2020
Interleukin-6 and total antioxidant capacity levels following <i>N</i>-acetylcysteine and a combination nutraceutical intervention in a randomised controlled trial for bipolar disorderC C Bortolasci, C Voigt, A Turner, et al.
Molecular Psychiatry|September 9, 2015
Citalopram and sertraline exposure compromises embryonic bone developmentD Fraher, J M Hodge, F M Collier, et al.
Neuroscience and Biobehavioral Reviews|October 12, 2010
Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factorsM Berk, F Kapczinski, A C Andreazza, et al.
Molecular Psychiatry|March 13, 2013
Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosisS Smesny, B Milleit, U-C Hipler, et al.
Molecular Psychiatry|February 23, 2022
A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophreniaA J McGuinness, J A Davis, S L Dawson, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|December 15, 2015
A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: A 12-month follow-up studyR Daglas, S M Cotton, K Allott, et al.
BMC Psychiatry|June 15, 2022
Counting on U training to enhance trusting relationships and mental health literacy among business advisors: protocol for a randomised controlled trialL Saxon, S Bromfield, S H Leow-Taylor, et al.
Trials|November 30, 2019
ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosisS M Cotton, M Berk, A Watson, et al.
Current Pharmaceutical Design|January 14, 2012
Rationale and first results of developing at-risk (prodromal) criteria for bipolar disorderA Bechdolf, A Ratheesh, S J Wood, et al.
Pageof 20

Showing results (181-190 of 196) with videos related to

Sort By:
Pageof 20
Journal of Internal Medicine|February 3, 2021
Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivorsR Méndez, V Balanzá-Martínez, S C Luperdi, et al.
Acta Neuropsychiatrica|July 1, 2020
Interleukin-6 and total antioxidant capacity levels following <i>N</i>-acetylcysteine and a combination nutraceutical intervention in a randomised controlled trial for bipolar disorderC C Bortolasci, C Voigt, A Turner, et al.
Molecular Psychiatry|September 9, 2015
Citalopram and sertraline exposure compromises embryonic bone developmentD Fraher, J M Hodge, F M Collier, et al.
Neuroscience and Biobehavioral Reviews|October 12, 2010
Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factorsM Berk, F Kapczinski, A C Andreazza, et al.
Molecular Psychiatry|March 13, 2013
Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosisS Smesny, B Milleit, U-C Hipler, et al.
Molecular Psychiatry|February 23, 2022
A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophreniaA J McGuinness, J A Davis, S L Dawson, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|December 15, 2015
A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: A 12-month follow-up studyR Daglas, S M Cotton, K Allott, et al.
BMC Psychiatry|June 15, 2022
Counting on U training to enhance trusting relationships and mental health literacy among business advisors: protocol for a randomised controlled trialL Saxon, S Bromfield, S H Leow-Taylor, et al.
Trials|November 30, 2019
ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosisS M Cotton, M Berk, A Watson, et al.
Current Pharmaceutical Design|January 14, 2012
Rationale and first results of developing at-risk (prodromal) criteria for bipolar disorderA Bechdolf, A Ratheesh, S J Wood, et al.
Pageof 20